— Know what they know.
Not Investment Advice

CGEM NASDAQ

Cullinan Therapeutics, Inc.
1W: -13.4% 1M: +1.0% 3M: +2.4% YTD: +38.1% 1Y: +77.0% 3Y: +53.1% 5Y: -49.5%
$13.84
-0.14 (-1.00%)
 
Weekly Expected Move ±10.4%
$12 $14 $16 $17 $19
NASDAQ · Healthcare · Medical - Pharmaceuticals · Alpha Radar Neutral · Power 42 · $850.6M mcap · 44M float · 1.96% daily turnover · Short 54% of daily vol

Cash Flow Trends

Operating Cash Flow
-$176M -21.0% ▼
Capital Expenditures
$49K +0.0% ▲
5Y CAGR: +37.4%
Free Cash Flow
-$176M -21.0% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$5M +134.5% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$67M$109M-$153M-$168M-$220M
Depreciation & Amort.$53K$93K$310K$306K$311K
Stock-Based Comp.$24M$28M$30M$38M$36M
Change in Working Capital-$4M$11M-$339K-$389K$14M
Other Non-Cash Items$67K-$275M-$12M-$15M-$6M
Operating Cash Flow-$43M-$127M-$134M-$145M-$176M
— Investing Activities —
Capital Expenditures-$589K-$1M-$208K$0-$49K
Acquisitions (Net)$923K$275M-$36K$0$0
Investment Purchases-$526M-$378M-$373M-$721M-$237M
Investment Sales$192M$353M$409M$585M$417M
Other Investing-$334K$91K$36K$0$0
Investing Cash Flow-$334M$249M$36M-$136M$180M
— Financing Activities —
Net Debt Issuance$0-$2M$2M$0$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$2M-$32M$538K$4M$0
Financing Cash Flow$269M-$26M$41M$266M$1M
Net Change in Cash-$108M$96M-$58M-$15M$5M
Cash End of Period$60M$156M$98M$83M$88M
Free Cash Flow-$44M-$128M-$134M-$145M-$176M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms